Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is back in the spotlight on December 3, 2025, after announcing positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD). The news has reignited hopes for eventual U.S. approval of the therapy and sent CAPR shares sharply higher in premarket trading. Capricor Therapeutics, Inc. With Wall…